Genomic Biomarkers Predict Response to Combined ATR Inhibition and Radiotherapy

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy

Background:

• Checkpoint kinase inhibitors have long been theorized for chemoradiosensitization but remain largely uninvestigated.
• Targeting DNA damage response pathways is a key strategy in cancer therapy.

Purpose of the Study:

• To investigate the efficacy of a novel ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, RP-3500, in combination with radiation therapy.
• To determine the genotype-specific effects of RP-3500 in radiosensitization.

Main Methods:

• In vivo studies using tumor models with different genetic backgrounds (Atm-/-, wild-type, Brca-1-deficient).
• Administration of the ATR kinase inhibitor RP-3500 in conjunction with radiation therapy.
• Assessment of tumor control and radiosensitization effects.

Main Results:

• The ATR inhibitor RP-3500 demonstrated synergistic effects with radiation, leading to significant control of Atm-/- tumors in vivo.
• RP-3500 did not exhibit radiosensitizing effects in wild-type or Brca-1-deficient tumors.
• These findings underscore the importance of genetic context in determining treatment response.

Conclusions:

• The novel ATR inhibitor RP-3500 shows promise as a radiosensitizer, particularly in tumors with ATM deficiency.
• A genotype-tailored approach is crucial for optimizing the clinical application of RP-3500 and similar targeted therapies.
• Further research is warranted to explore the full potential of ATR inhibitors in combination cancer treatment.